KCNA3 and autoimmune disease: It blocks Kv1.3 highly selectively and its analogs have been used as a therapeutic for autoimmune diseases.[10] ShK is highly homologous to a domain of MMP23, and is likely recognized by the immune system as a self‐peptide, which has been successfully used in genetically engineered probiotic delivery systems.[11] However, there is no evidence to indicate whether aberrantly Kv1.3 expression in activated M1‐like macrophages and OA progression.